JPRN-UMIN000008702已完成2 期
A randomized phase2 study of bendamustine monotherapy for relapsing or refractory low-grade B-cell non-Hodgkin's lymphoma or mantle cell lymphoma comparing administration schedule. - RABBIT-14
Shimousa blood study group0 个研究点目标入组 54 人开始时间: 2012年8月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Pregnant women or nursing mothers. In postmenopausal women within a year. Women and men who cannot prevent pregnancy or do not have intension to prevent during the treatment period 2.With active double cancer (synchronous double cancer or metachronous double cancer which have 5-years of disease-free, except for basal cell carcinoma, squamous cell carcinoma, carcinoma in situ which goes into remission by topical treatment, or lesion part equivalent to intramucosal carcinoma.) 3.With mental disease or neurologic manifestation considered to be difficult to participate in this study. 4.HBs antigen positive. 5.HIV antibody-positive. 6.With a lot of tumor cells in peripheral blood (more than 25,000/µL). 7.having received hematopoietic stem cell transplantation. 8.With interstitial pneumonia, radiation pneumonia, or pulmonary fibrosis on the chest CT scan (within 3-months before registration). 9.With CNS infiltration. 10.Have experience with bendamustine treatment or diagnosed unsuitable for bendamustine treatment. 11.With severe drug hypersensitivity. 12.Judged as inappropriate for this study by the investigator.
研究者
相似试验
已完成
2 期
A randomized phase2 study of bendamustine plus Rituximab for relapsing or refractory follicular lymphoma comparing 90 mg/sqm BR vs. 120 mg/sqm BR.Follicular lymphomaJPRN-UMIN000009243Juntendo, Yamanashi Clinical Study Group36
进行中（未招募）
1 期
Study of bendamustine in patients aged over 60 years with classical Hodgkin lymphoma treated by prednisone, vinblastine and doxorubiciEUCTR2014-001002-17-BEYSARC90
进行中（未招募）
不适用
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s LymphomaPatients with advanced untreated Indolent non Follicular non-Hodgkin LymphomasMedDRA version: 14.1Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019248-37-ITFONDAZIONE ITALIANA LINFOMI ONLUS
进行中（未招募）
不适用
Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia - BEN-CAMEUCTR2008-001824-30-ITAssociazione Malattie Sangue Onlus
招募中
2 期
Clinical trials for HDC / ASCT indication rrDLBCRelapsed or recurrent diffuse large B-cell lymphomaJPRN-jRCTs071210121Terui Yasuhito20